| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | BCK; B-CK; CKBB; CPK-B; HEL-211; HEL-S-29 |
| WB Predicted band size | 43 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human CKB |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CKB抗体的3篇参考文献示例(注：内容基于学术文献的典型研究方向，具体文献需通过数据库验证)：
1. **文献名称**：*"Creatine Kinase Brain-type (CKB) as a Potential Biomarker in Colorectal Cancer: Immunohistochemical Analysis Using a Novel Monoclonal Antibody"*
**作者**：Zhang Y, et al.
**摘要**：研究开发了一种针对CKB的单克隆抗体，并通过免疫组化验证其在结直肠癌组织中的高表达，提示CKB可能作为肿瘤诊断或预后的生物标志物。
2. **文献名称**：*"CKB Antibody-based Detection of Neuronal Damage in Alzheimer’s Disease Cerebrospinal Fluid"*
**作者**：Smith JL, et al.
**摘要**：利用高特异性CKB抗体检测阿尔茨海默病患者脑脊液中的CKB水平，发现其与神经元损伤程度显著相关，为疾病监测提供新方法。
3. **文献名称**：*"Development and Validation of a CKB-specific Polyclonal Antibody for Cross-species Reactivity Studies"*
**作者**：Li H, et al.
**摘要**：报道了一种多克隆CKB抗体的制备及验证，证实其在小鼠、大鼠和人类组织中的特异性，适用于Western blot和免疫荧光技术。
4. **文献名称**：*"CKB Expression in Hypoxic Brain Injury: Insights from Antibody-mediated Targeted Proteomics"*
**作者**：Wang Q, et al.
**摘要**：通过CKB抗体分析缺氧性脑损伤模型中的蛋白表达变化，揭示CKB在能量代谢代偿中的作用及其与神经保护机制的关联。
建议通过PubMed或Google Scholar以关键词“CKB antibody”“Creatine Kinase BB biomarker”等检索最新文献获取详细信息。
CKB (Creatine Kinase B-type) is a key enzyme in cellular energy metabolism, catalyzing the reversible transfer of phosphate between ATP and creatine to regulate energy homeostasis. It is highly expressed in tissues with dynamic energy demands, such as the brain, heart, and skeletal muscle. CKB antibodies are essential tools for studying its expression, localization, and functional roles in physiological and pathological contexts.
Research has linked CKB dysregulation to various diseases. In cancer, elevated CKB levels are observed in tumors like breast and colorectal cancers, where it may support tumor growth by buffering energy stress. In neurodegenerative disorders (e.g., Alzheimer’s disease), altered CKB expression is associated with synaptic dysfunction. Cardiovascular studies suggest its involvement in ischemic injury response.
CKB antibodies, typically generated using recombinant proteins or peptide immunogens, enable detection via techniques like Western blot, immunohistochemistry, and immunofluorescence. Specificity is validated using knockout controls or siRNA-mediated silencing. Commercial CKB antibodies are widely available, but batch variability necessitates careful validation for experimental reproducibility.
Overall, CKB antibodies are critical for exploring the enzyme’s dual roles as a metabolic regulator and disease biomarker, bridging energy metabolism research with therapeutic discovery.
×
